2020
DOI: 10.1101/2020.04.21.052647
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Abstract: Background and aimsEsophageal adenocarcinoma (EAC) is chemoresistant in the majority of cases. The tumor-promoting biology of cancer associated fibroblasts (CAF) make them a target for novel therapies. Phosphodiesterase type 5 inhibitors (PDE5i) have been shown to regulate the activated fibroblast phenotype in benign disease. We investigated the potential for CAF modulation in EAC using PDE5i to enhance the efficacy of chemotherapy.MethodsEAC fibroblasts were treated with PDE5i and phenotypic effects examined … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 49 publications
0
1
0
Order By: Relevance
“…Single cell proteomic assays confirmed previous sequencing findings regarding the relative effects of repurposed drugs tivantinib, PHA-665752 and crizontinib. Single cell RNASEq and single cell shotgun proteomics have also been used in combination to discern the role of cancer associated fibroblasts in chemoresistance inesophageal adenocarcinoma ( 161 ). This study shows that phosphodiesterase 5 inhibitors are able to regulate the activated fibroblasts phenotypes in the benign disease and are promising drugs to enhance response to chemotherapy.…”
Section: Discussionmentioning
confidence: 99%
“…Single cell proteomic assays confirmed previous sequencing findings regarding the relative effects of repurposed drugs tivantinib, PHA-665752 and crizontinib. Single cell RNASEq and single cell shotgun proteomics have also been used in combination to discern the role of cancer associated fibroblasts in chemoresistance inesophageal adenocarcinoma ( 161 ). This study shows that phosphodiesterase 5 inhibitors are able to regulate the activated fibroblasts phenotypes in the benign disease and are promising drugs to enhance response to chemotherapy.…”
Section: Discussionmentioning
confidence: 99%